Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01955733 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT01955733 is a Phase 3 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 91 participants.
The verdict
NCT01955733, a Phase 3 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.
Interventions
- DRUG BI 695500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2013-05-31 |
| Est. Completion | 2016-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01955733
The ClinicalTrials.gov registry entry for NCT01955733 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 695500 is the first listed.
NCT01955733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01955733 about?
NCT01955733 is a clinical study titled "Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis". The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.
What is the current status of trial NCT01955733?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2013-05-31. Estimated completion is 2016-11-07.
What interventions are being tested in trial NCT01955733?
The interventions under investigation include: BI 695500 (DRUG).
Who is sponsoring clinical trial NCT01955733?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.